Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
KAI Pharmaceuticals
KAI Pharmaceuticals
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Parsabiv
Etelcalcetide
2017-02-07
2030-2034
Secondary hyperparathyroidism
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Etelcalcetide
chronic kidney failure
,
neoplasm metastasis
,
secondary hyperparathyroidism
,
hyperparathyroidism
,
chronic renal insufficiency
,
kidney diseases
,
left ventricular hypertrophy
,
cardiomegaly
,
hypertrophy
Benzocaine
healthy volunteers/patients
,
atopic dermatitis
,
crohn disease
,
eczema
,
dermatitis
,
alzheimer disease
,
psoriasis
,
epilepsy
,
psoriatic arthritis
,
seizures
,
arthritis
,
spondylarthritis
,
spondylitis
,
ankylosing spondylitis
,
axial spondyloarthritis
,
drug resistant epilepsy
,
restless legs syndrome
,
psychomotor agitation
,
syndrome
,
rheumatoid arthritis
,
partial epilepsies
,
complex partial epilepsy
,
absence epilepsy
,
spondylarthropathies
,
chronic kidney failure
,
kidney diseases
,
myelin oligodendrocyte glycoprotein antibody-associated disease
,
parkinson disease
,
chronic pain
,
lethargy
,
sleep wake disorders
DELCASERTIB
cardiovascular diseases
,
myocardial infarction
,
infarction
,
pathologic processes
Histone-arginine methyltransferase carm1
pancreatic neoplasms
,
stomach neoplasms
,
neuroendocrine tumors
,
intestinal neoplasms
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use